This paper describes an organization, The Institute of Health Economics in Alberta, Canada, that has been created by multisectoral collaboration and is engaged in pharmacoeconomics and outcomes research and applications. Since its establishment, a number of academic researchers have been attracted to Alberta from elsewhere. A multisectoral process (that incorporates both quality and relevance) of developing research programs has been implemented. Multidisciplinary and multicenter groups are being put together to undertake research programs in disease-specific areas. Some of these will provide help to government decision makers regarding the introduction of new, expensive health technologies. Studies are also underway to try and improve drug compliance, particularly among the elderly.
Challenges faced include the different time frames that decision makers and researchers have for research projects. It has also been a challenge translating expressed research needs of “users” to meaningful research questions. However, the structure of the institute has enabled such obstacles to be clearly defined and addressed.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Assiff L, Pollock MR, Manzi P, et al. Health economics in the Canadian pharmaceutical industry. PharmacoEcon 1999;16:669–678.
Andersson F. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Intl J Technol Assessment Health Care. 1995;2:750–761.
Griffin JP. The need for pharmacoeconomic evaluation in the NHS. PharmacoEcon 1998;14:241–250.
Chiang PJ, Einarson TR. A survey of pharmacoeconomics in the Canadian pharmaceutical industry. Drug Inf J 1998;32:619–627.
Drummond M. A reappraisal of economic evaluation of pharmaceuticals: science or marketing? PharmacoEcon. 1998;14:1–9.
Byford S, Torgerson DT, Raftery J. Cost of illness studies. Br Med J 2000;320:1335.
Hillman A, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New Engl J Med 1991;324:1362–1365.
Goldbeck-Wood P. Drug company loses battle to stop article. Br Med J 1997;315:1563.
Hemminki E, Hailey D, Koivusalo M. The courts— A challenge to health technology assessment. Science 1999;285:203–204.
Cooke J, Walley T, Drummond MF. The use of health economics by hospital pharmacist decision makers—a survey of U. chief pharmacists. Pharmaceutical J 1997;259:779–781.
Hoffmann C, von der Schulenberg JG. The influence of economic evaluation studies on decision makers. A European study. Health Policy 2000;52:179–192.
Hurst J. The impact of health economics on health policy in England, and the impact of health policy on health economics, 1972–1997. Health Economics 1998;7:S47–S62.
About this article
Cite this article
Menon, D., Gebran, J. Pharmacoeconomics and Outcomes Research—Is Intersectoral Collaboration Possible?. Ther Innov Regul Sci 36, 239–244 (2002). https://doi.org/10.1177/009286150203600128
- Outcomes research